Overview
Hereditary sensory and autonomic neuropathy type 4 (HSAN4), also known as congenital insensitivity to pain with anhidrosis (CIPA), is a rare autosomal recessive disorder caused by mutations in the NTRK1 gene (also called TRKA), which encodes the neurotrophic tyrosine kinase receptor type 1. This receptor is essential for the development and survival of sympathetic postganglionic neurons and nociceptive sensory neurons. The condition is characterized by the absence of pain sensation (insensitivity to pain), inability to sweat (anhidrosis), and intellectual disability of variable severity. Because the autonomic nervous system is affected, patients cannot regulate body temperature through sweating, leading to recurrent episodes of unexplained high fevers (hyperthermia), which can be life-threatening, particularly in infancy and early childhood. The insensitivity to pain results in repeated injuries, fractures, burns, and self-mutilating behaviors such as biting of the tongue, lips, and fingers. Patients frequently develop skin ulcers, joint deformities (Charcot joints), and osteomyelitis due to unrecognized trauma and infections. Corneal scarring from unnoticed eye injuries may also occur. The peripheral nervous system is primarily affected, with loss of small myelinated and unmyelinated nerve fibers. Thick skin and hyperkeratosis of the palms and soles are common findings. There is currently no cure or disease-modifying treatment for HSAN4. Management is supportive and multidisciplinary, focusing on prevention and early treatment of injuries, infections, and overheating. Temperature regulation through environmental control is critical. Dental care is important to prevent self-inflicted oral injuries. Orthopedic monitoring is necessary to manage fractures and joint complications. Families and caregivers must be educated about the risks associated with the inability to perceive pain and the importance of vigilant supervision, especially during childhood.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Hereditary sensory and autonomic neuropathy type 4.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hereditary sensory and autonomic neuropathy type 4 at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hereditary sensory and autonomic neuropathy type 4.
Community
No community posts yet. Be the first to share your experience with Hereditary sensory and autonomic neuropathy type 4.
Start the conversation →Latest news about Hereditary sensory and autonomic neuropathy type 4
No recent news articles for Hereditary sensory and autonomic neuropathy type 4.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hereditary sensory and autonomic neuropathy type 4
What is Hereditary sensory and autonomic neuropathy type 4?
Hereditary sensory and autonomic neuropathy type 4 (HSAN4), also known as congenital insensitivity to pain with anhidrosis (CIPA), is a rare autosomal recessive disorder caused by mutations in the NTRK1 gene (also called TRKA), which encodes the neurotrophic tyrosine kinase receptor type 1. This receptor is essential for the development and survival of sympathetic postganglionic neurons and nociceptive sensory neurons. The condition is characterized by the absence of pain sensation (insensitivity to pain), inability to sweat (anhidrosis), and intellectual disability of variable severity. Becau
How is Hereditary sensory and autonomic neuropathy type 4 inherited?
Hereditary sensory and autonomic neuropathy type 4 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hereditary sensory and autonomic neuropathy type 4 typically begin?
Typical onset of Hereditary sensory and autonomic neuropathy type 4 is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Hereditary sensory and autonomic neuropathy type 4?
12 specialists and care centers treating Hereditary sensory and autonomic neuropathy type 4 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.